Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 17

1.

Nose-to-brain drug delivery: An update on clinical challenges and progress towards approval of anti-Alzheimer drugs.

Agrawal M, Saraf S, Saraf S, Antimisiaris SG, Chougule MB, Shoyele SA, Alexander A.

J Control Release. 2018 Jul 10;281:139-177. doi: 10.1016/j.jconrel.2018.05.011. Epub 2018 May 24. Review.

PMID:
29772289
2.

Intranasal deferoxamine affects memory loss, oxidation, and the insulin pathway in the streptozotocin rat model of Alzheimer's disease.

Fine JM, Forsberg AC, Stroebel BM, Faltesek KA, Verden DR, Hamel KA, Raney EB, Crow JM, Haase LR, Knutzen KE, Kaczmarczek KD, Frey WH, Hanson LR.

J Neurol Sci. 2017 Sep 15;380:164-171. doi: 10.1016/j.jns.2017.07.028. Epub 2017 Jul 21.

PMID:
28870559
3.

Linking multiple pathogenic pathways in Alzheimer's disease.

Bou Khalil R, Khoury E, Koussa S.

World J Psychiatry. 2016 Jun 22;6(2):208-14. doi: 10.5498/wjp.v6.i2.208. eCollection 2016 Jun 22. Review.

4.

Deferoxamine-mediated up-regulation of HIF-1α prevents dopaminergic neuronal death via the activation of MAPK family proteins in MPTP-treated mice.

Guo C, Hao LJ, Yang ZH, Chai R, Zhang S, Gu Y, Gao HL, Zhong ML, Wang T, Li JY, Wang ZY.

Exp Neurol. 2016 Jun;280:13-23. doi: 10.1016/j.expneurol.2016.03.016. Epub 2016 Mar 18.

PMID:
26996132
5.

Intranasal deferoxamine attenuates synapse loss via up-regulating the P38/HIF-1α pathway on the brain of APP/PS1 transgenic mice.

Guo C, Zhang YX, Wang T, Zhong ML, Yang ZH, Hao LJ, Chai R, Zhang S.

Front Aging Neurosci. 2015 Jun 2;7:104. doi: 10.3389/fnagi.2015.00104. eCollection 2015.

6.

Intranasal deferoxamine engages multiple pathways to decrease memory loss in the APP/PS1 model of amyloid accumulation.

Fine JM, Renner DB, Forsberg AC, Cameron RA, Galick BT, Le C, Conway PM, Stroebel BM, Frey WH 2nd, Hanson LR.

Neurosci Lett. 2015 Jan 1;584:362-7. doi: 10.1016/j.neulet.2014.11.013. Epub 2014 Nov 13.

PMID:
25445365
7.

Zn/Ga-DFO iron-chelating complex attenuates the inflammatory process in a mouse model of asthma.

Bibi H, Vinokur V, Waisman D, Elenberg Y, Landesberg A, Faingersh A, Yadid M, Brod V, Pesin J, Berenshtein E, Eliashar R, Chevion M.

Redox Biol. 2014 Jun 18;2:814-9. doi: 10.1016/j.redox.2014.06.009. eCollection 2014.

8.

Intranasally-administered deferoxamine mitigates toxicity of 6-OHDA in a rat model of Parkinson׳s disease.

Fine JM, Forsberg AC, Renner DB, Faltesek KA, Mohan KG, Wong JC, Arneson LC, Crow JM, Frey WH 2nd, Hanson LR.

Brain Res. 2014 Jul 29;1574:96-104. doi: 10.1016/j.brainres.2014.05.048. Epub 2014 Jun 10.

PMID:
24928620
9.

Intranasal administration of CNS therapeutics to awake mice.

Hanson LR, Fine JM, Svitak AL, Faltesek KA.

J Vis Exp. 2013 Apr 8;(74). doi: 10.3791/4440.

10.

Chronic intranasal deferoxamine ameliorates motor defects and pathology in the α-synuclein rAAV Parkinson's model.

Febbraro F, Andersen KJ, Sanchez-Guajardo V, Tentillier N, Romero-Ramos M.

Exp Neurol. 2013 Sep;247:45-58. doi: 10.1016/j.expneurol.2013.03.017. Epub 2013 Mar 24.

PMID:
23531432
11.

Deferoxamine inhibits iron induced hippocampal tau phosphorylation in the Alzheimer transgenic mouse brain.

Guo C, Wang P, Zhong ML, Wang T, Huang XS, Li JY, Wang ZY.

Neurochem Int. 2013 Jan;62(2):165-72. doi: 10.1016/j.neuint.2012.12.005. Epub 2012 Dec 20.

PMID:
23262393
12.

Intranasal deferoxamine reverses iron-induced memory deficits and inhibits amyloidogenic APP processing in a transgenic mouse model of Alzheimer's disease.

Guo C, Wang T, Zheng W, Shan ZY, Teng WP, Wang ZY.

Neurobiol Aging. 2013 Feb;34(2):562-75. doi: 10.1016/j.neurobiolaging.2012.05.009. Epub 2012 Jun 19.

PMID:
22717236
13.

Intranasal delivery of deferoxamine reduces spatial memory loss in APP/PS1 mice.

Hanson LR, Fine JM, Renner DB, Svitak AL, Burns RB, Nguyen TM, Tuttle NJ, Marti DL, Panter SS, Frey WH 2nd.

Drug Deliv Transl Res. 2012 Jun;2(3):160-8. doi: 10.1007/s13346-011-0050-2.

PMID:
25786865
14.

Intranasal deferoxamine improves performance in radial arm water maze, stabilizes HIF-1α, and phosphorylates GSK3β in P301L tau transgenic mice.

Fine JM, Baillargeon AM, Renner DB, Hoerster NS, Tokarev J, Colton S, Pelleg A, Andrews A, Sparley KA, Krogh KM, Frey WH, Hanson LR.

Exp Brain Res. 2012 Jun;219(3):381-90. doi: 10.1007/s00221-012-3101-0. Epub 2012 May 1.

PMID:
22547371
15.

Intranasal deferoxamine provides increased brain exposure and significant protection in rat ischemic stroke.

Hanson LR, Roeytenberg A, Martinez PM, Coppes VG, Sweet DC, Rao RJ, Marti DL, Hoekman JD, Matthews RB, Frey WH 2nd, Panter SS.

J Pharmacol Exp Ther. 2009 Sep;330(3):679-86. doi: 10.1124/jpet.108.149807. Epub 2009 Jun 9.

16.
17.

Intranasal administration of deferoxamine to iron overloaded patients.

Gordon GS, Ambruso DR, Robinson WA, Githens JH.

Am J Med Sci. 1989 May;297(5):280-4. Erratum in: Am J Med Sci 1990 Jul;300(1):32.

PMID:
2640419

Supplemental Content

Loading ...
Support Center